[Worldkings] Top 200 breakthrough research works in the world (P. 50) Monash University creates a breakthrough pill capable of rapidly reducing bad cholesterol levels in 24 hours (Australia)


(Worldkings.org) Researchers from Monash University have unveiled a pill capable of reducing bad cholesterols within 24 hours.

Researchers from Monash University have unveiled a groundbreaking achievement: a pill capable of significantly reducing elevated levels of 'lipoprotein(a)' or Lp(a), commonly known as bad cholesterol, within just 24 hours from the first dose.

The innovation, named Muvalaplin, marks the pioneering creation of an oral drug that specifically targets lipoprotein(a). The remarkable effectiveness was showcased through a rigorous trial that confirmed its potential to address a crucial cardiovascular risk factor.


(Photo for illustration)


This remarkable advancement holds the promise of transforming the landscape of high cholesterol management and stands as a potential preventive measure against heart-related diseases, often linked to elevated levels of harmful cholesterol. 

Lipoprotein(a), commonly referred to as Lp(a) or 'LP little a', affects a lot of people, yet there is currently no approved treatment available. However, a groundbreaking trial has showcased the potential of Muvalaplin, an innovative oral medication specifically designed to target Lp(a), to significantly address this concern.

Impressively, Muvalaplin has demonstrated its efficacy in reducing Lp(a) levels by up to 65 percent, marking the first-ever oral drug with such capabilities. Its mechanism revolves around disrupting the formation of Lp(a) within the body.

The remarkable success of this trial can be attributed to the visionary leadership of Professor Stephen Nicholls, a distinguished cardiologist and the Director of Monash University's Victorian Heart Institute and the Victorian Heart Hospital at Monash Health.

The results of this landmark research and trial were unveiled at the European Society of Cardiology Congress in Amsterdam and have now been published in JAMA, underscoring the significant potential of Muvalaplin in reshaping the approach to managing Lp(a) levels.


(Photo for illustration)


The drug is set to advance to larger-scale clinical trials. Moreover, its potential applications might extend to the treatment of other vascular and valve-related conditions. However, the study has some limitations. Researchers need to conduct larger and longer trials to ensure the pill's safety and effectiveness in different groups of people.

The study also focused on people with lower to moderate Lp(a) levels, and it's unclear if the pill will reduce the risk of heart problems. This discovery is a step forward, but more research is needed to fully understand its potential. 


According to techtimes.com

Kyna ( Collect) - WORLDKINGS (Source of photos: Internet)


towerWorldKings journeys
CAMBODIA BOOK OF RECORDSWorld Records University